#China #Shanghai #WuXi XDC #CRDMO #bioconjugates

WuXi XDC Shows Robust Growth in H1 2025

WuXi XDC Cayman Inc., a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in bioconjugates, has reported remarkable growth in its financial and operational metrics for the first half of 2025. The company's latest interim results underline its strong position in the bioconjugate market, reflecting both an increase in revenue and a growing customer base.

Financial Highlights

WuXi XDC witnessed a staggering 62.2% year-over-year increase in its revenue, which reached RMB 2,701 million for the six months ending June 30, 2025. This growth is largely attributed to the following factors:
1. An expanding customer base, which now totals 563, including partnerships with 13 of the top 20 global pharmaceutical companies.
2. An increasing number of projects driven by the growing demand in the bioconjugates market, particularly Antibody-Drug Conjugates (ADCs).
3. Continuous improvements in the operational efficiency and manufacturing processes.

Furthermore, WuXi XDC's gross profit soared by 82.2% year-over-year, achieving RMB 975 million with a gross profit margin of 36.1%. These impressive figures showcase the effectiveness of the company’s strategies and the positive impacts of their enhanced production capabilities.

WuXi XDC also reported an adjusted net profit before interest income and expense that rose by 69.6% to RMB 733 million, illustrating a profit margin improvement to 27.1%. When accounting for interest income and expense, the adjusted net profit grew by 50.1% to RMB 801 million, maintaining a margin of 29.6%.

Expansion of Customer Base and Projects

The first half of 2025 has been pivotal for WuXi XDC as the group signed 37 new integrated CMC (iCMC) projects, bringing the total number of iCMC projects to 225. This marked growth is a testament to the group’s effective strategy of “Enable, Follow, and Win the Molecule.” The successful acquisition of these contracts showcases the company’s innovative approach to meet the unique needs of its diverse clientele.

Among its recent endeavors, WuXi XDC achieved a significant milestone with the GMP (Good Manufacturing Practice) release of its DP3 facility, further enhancing its integrated manufacturing capabilities. In addition, the new site in Singapore has reached mechanical completion and is slated for GMP release in the first half of 2026.

Innovations and Future Outlook

In striving to be a frontrunner in the development of bioconjugates, WuXi XDC emphasizes investment in cutting-edge technologies. The proprietary WuXiDARx™ technology aims to satisfy the demand for highly homogeneous ADCs, and a novel linker-payload approach is being developed to improve stability and efficacy. These innovations position the company favorably, as it continues to explore advanced modalities such as bispecific ADCs and dual-payload ADCs.

WuXi XDC's CEO, Dr. Jimmy Li, expressed confidence in the company’s trajectory, emphasizing a commitment to innovation and high-quality service delivery, which he believes is fundamental to maintaining a competitive edge in the industry.

Recognition and Awards

In addition to its impressive financial results, WuXi XDC's accomplishments have not gone unnoticed; the group has received multiple accolades from the 2025 Asia (ex-Japan) Best Executive Team by Extel. Such recognition highlights the firm’s commitment to corporate governance and investor relations, further enhancing its reputation within the global market.

Conclusion

WuXi XDC continues to demonstrate significant progress in the bioconjugates sector with robust revenue growth, an expanding customer portfolio, and advancements in innovative technologies. As the company prepares for a future filled with potential breakthroughs, it remains dedicated to elevating the standards of bioconjugate development and manufacturing. WuXi XDC is firmly positioned to lead the way in bioconjugate innovation, ensuring continued value to its customers and stakeholders alike.